cd8 apc cy7 Search Results


cd8 polyclonal antibody, apc-cy7 conjugated  (Bioss)
N/A
Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3
   Buy from Supplier
cd8 (sk1, 5ul)  (Becton Dickinson)
90
Becton Dickinson cd8 (sk1, 5ul)
The mean (±SEM) percent Ki67+ (A+B) and percent BrdU+ (C+D) of peripheral blood CD4+ (A+C) and <t>CD8+</t> (B+D) T-cells were assessed longitudinally by flow cytometry in both uninfected (black squares) and infected (red circles) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.
Cd8 (Sk1, 5ul), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8+apc+cy7/cd8+sk1++apc+199+cy7+antibody/pmc04881966-88-25-35
Average 90 stars, based on 1 article reviews
cd8 (sk1, 5ul) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-cd8-apc-cy7  (QuantoBio)
90
QuantoBio anti-cd8-apc-cy7
The mean (±SEM) percent Ki67+ (A+B) and percent BrdU+ (C+D) of peripheral blood CD4+ (A+C) and <t>CD8+</t> (B+D) T-cells were assessed longitudinally by flow cytometry in both uninfected (black squares) and infected (red circles) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.
Anti Cd8 Apc Cy7, supplied by QuantoBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8+apc+cy7/anti+cd8+apc+cy7/pmc08924605-59-10-11
Average 90 stars, based on 1 article reviews
anti-cd8-apc-cy7 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-human cd8 antibody pharmin, apc-cy™7  (Becton Dickinson)
90
Becton Dickinson anti-human cd8 antibody pharmin, apc-cy™7
CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and <t>CD8</t> (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.
Anti Human Cd8 Antibody Pharmin, Apc Cy™7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8+apc+cy7/anti+human+cd8+antibody+pharmin++apc+cy+7/bio_rxiv__2022__03__01__482445-143-6-9
Average 90 stars, based on 1 article reviews
anti-human cd8 antibody pharmin, apc-cy™7 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
apc cy 7 mouse anti human cd8  (BD Biosciences)
N/A
   Buy from Supplier
apc/cy7 anti-human cd8  (BioLegend)
N/A
APC/Cy7 anti-human CD8 [SK1]; Isotype: Mouse IgG1, κ; Reactivity: Human, Cross-Reactivity: African Green, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus, Sooty Mangabey ; Apps: FC; Size: 25 tests
   Buy from Supplier
cd8 (hit8a) monoclonal antibody, apc-cy7 conjugated  (Bioss)
N/A
The CD8 antigen is a cell surface glycoprotein found on most cytotoxic T lymphocytes that mediates efficient cell to cell interactions within the immune system. The CD8 antigen, acting as a coreceptor, and the T
   Buy from Supplier
cd8 apc cy 7  (BD Biosciences)
N/A
CD8 clone SK1 is derived from hybridization of mouse NS 1 myeloma cells with spleen cells from BALB c mice immunized with human peripheral blood T lymphocytes CD8 clone SK1 is derived from hybridization of
   Buy from Supplier

Image Search Results


The mean (±SEM) percent Ki67+ (A+B) and percent BrdU+ (C+D) of peripheral blood CD4+ (A+C) and CD8+ (B+D) T-cells were assessed longitudinally by flow cytometry in both uninfected (black squares) and infected (red circles) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Journal: PLoS ONE

Article Title: Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys

doi: 10.1371/journal.pone.0156352

Figure Lengend Snippet: The mean (±SEM) percent Ki67+ (A+B) and percent BrdU+ (C+D) of peripheral blood CD4+ (A+C) and CD8+ (B+D) T-cells were assessed longitudinally by flow cytometry in both uninfected (black squares) and infected (red circles) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Article Snippet: Mouse-derived monoclonal antibodies directed against the following antigens were used at titration-assessed volumes as follows: BrdU (clone 3D4, 20uL), CCR5 (3A9, 10uL), CD3 (SP34-2, 5uL), CD8 (SK1, 5uL), CD62L (SK11, 10uL), Ki67 (B56, 20uL) from BD Biosciences Pharmingen, CD4 (OKT4, 5uL) from BioLegend, CD28 (CD28.2, 10uL) from Beckman-Coulter, and CD95 (DX2, 10uL) from eBioscience.

Techniques: Flow Cytometry, Infection, MANN-WHITNEY

A-B. (±SEM) percent BrdU expression was assessed longitudinally by flow cytometry among CD4+ (A) and CD8+ (B) T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. C. Mean (±SEM) longitudinal Ki67 expression of CD4+ T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Journal: PLoS ONE

Article Title: Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys

doi: 10.1371/journal.pone.0156352

Figure Lengend Snippet: A-B. (±SEM) percent BrdU expression was assessed longitudinally by flow cytometry among CD4+ (A) and CD8+ (B) T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. C. Mean (±SEM) longitudinal Ki67 expression of CD4+ T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Article Snippet: Mouse-derived monoclonal antibodies directed against the following antigens were used at titration-assessed volumes as follows: BrdU (clone 3D4, 20uL), CCR5 (3A9, 10uL), CD3 (SP34-2, 5uL), CD8 (SK1, 5uL), CD62L (SK11, 10uL), Ki67 (B56, 20uL) from BD Biosciences Pharmingen, CD4 (OKT4, 5uL) from BioLegend, CD28 (CD28.2, 10uL) from Beckman-Coulter, and CD95 (DX2, 10uL) from eBioscience.

Techniques: Expressing, Flow Cytometry, Infection, MANN-WHITNEY

CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and CD8 (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and CD8 (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Activity Assay, In Vivo, Staining

1XX modification of AXL CAR enhance its anti-tumor activity in a melanoma tumor model. (a) Timeline of of AXL CAR-T treatment in mouse model. (b) A375-bearing mice were treated with 2.5 × 10 6 AXL CAR-T cells and tumor burden (tumor volume) of mice were measured at indicated days (n=4, 5, 5 mice in respective groups). Control, PBS. (c) Tumor tissue of mice treated with indicated CAR-T cells (n=4, 5, 5). (d) The weight of tumors from different groups of mice (n=4, 5, 5). Number of CAR-T(e), CD4 + CAR-T cells (f) and CD8 + CAR-T cells (g) in spleen of mice 20 days post CAR-T infusion (n=5, 3). (h-k) Phenotype of CAR-T cells in the spleen of mice 20 days after CAR-T infusion as demonstrated by the percentage of T CM (CD45RA - CD62L + ) and T EFF (CD45RA + CD62L - ) cells (n=5, 3). All data are mean ± SEM.

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: 1XX modification of AXL CAR enhance its anti-tumor activity in a melanoma tumor model. (a) Timeline of of AXL CAR-T treatment in mouse model. (b) A375-bearing mice were treated with 2.5 × 10 6 AXL CAR-T cells and tumor burden (tumor volume) of mice were measured at indicated days (n=4, 5, 5 mice in respective groups). Control, PBS. (c) Tumor tissue of mice treated with indicated CAR-T cells (n=4, 5, 5). (d) The weight of tumors from different groups of mice (n=4, 5, 5). Number of CAR-T(e), CD4 + CAR-T cells (f) and CD8 + CAR-T cells (g) in spleen of mice 20 days post CAR-T infusion (n=5, 3). (h-k) Phenotype of CAR-T cells in the spleen of mice 20 days after CAR-T infusion as demonstrated by the percentage of T CM (CD45RA - CD62L + ) and T EFF (CD45RA + CD62L - ) cells (n=5, 3). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Modification, Activity Assay